Last reviewed · How we verify
ISV-305
ISV-305 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway.
ISV-305 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway. Used for Oncology indication (specific indication not publicly confirmed).
At a glance
| Generic name | ISV-305 |
|---|---|
| Sponsor | Sun Pharmaceutical Industries Limited |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific mechanistic details for ISV-305 are limited in public literature, Sun Pharmaceutical's immunotherapy pipeline typically focuses on checkpoint inhibitors or immune-modulating agents. The drug is in Phase 3 development, suggesting it has demonstrated preliminary efficacy in earlier trials. Exact molecular targets and mechanism require access to clinical trial protocols or company disclosures.
Approved indications
- Oncology indication (specific indication not publicly confirmed)
Common side effects
Key clinical trials
- Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery (PHASE3)
- 2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery (PHASE3)
- Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISV-305 CI brief — competitive landscape report
- ISV-305 updates RSS · CI watch RSS
- Sun Pharmaceutical Industries Limited portfolio CI